Tag: AstraZeneca

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

Russia is one of the key markets for the company “AstraZeneca”. In October 2015 in the Kaluga region took place the grand opening of the company’s plant in Russia. Total investment in the creation of the company was $224 million. In addition, “AstraZeneca” is one of the largest companies that invest in scientific and research activities. In Russia, company conducts clinical research, which today includes more than six thousand patients. Seven and a half thousand patients participating in company studies, clinical practice. In 2016 company expanded scientific cooperation with Russian Society of Clinical Oncology and continued partnership with “Skolkovo” biomedcluster.

AstraZeneca sold rights for Seloken drug to Recordati

astrazeneca
AstraZeneca announced today that it has entered into an agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken.

Skolkovo Foundation and AstraZeneca sign a strategic partnership agreement

astrazeneca-skolkovo
Skolkovo Foundation and AstraZeneca, an international biopharmaceutical company, have agreed on a strategic partnership in the area of research and educational activities in Russia. The parties int...

AstraZeneca reported successful clinical trial of lung cancer drug

astrazeneca
AstraZeneca and MedImmune, its global biologics research and development arm, have announced positive results for a trial of its lung cancer drug Imfinzi (durvalumab). The phase III PACIFIC tri...

AstraZeneca will develop respiratory drug with Pieris Pharmaceuticals

astrazeneca
Pieris announced a strategic collaboration in respiratory diseases with AstraZeneca to develop novel inhaled drugs that leverage Pieris' Anticalin platform, including its lead preclinical drug candida...

AstraZeneca opened strategic R&D centre in Cambridge, UK

astrazeneca
AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the ‘topping out’ of its new, state-of-the-art, strategic R&D centre and global corporate headquarters at the heart ...

Lung cancer drug received approval in China

astrazeneca
AstraZeneca announced that the China Food and Drug Administration (CFDA) has granted marketing authorisation for Tagrisso (osimertinib) 40 mg and 80mg once-daily oral tablets for the treatment of adul...

AstraZeneca’s Durvalumab monotherapy confirm results in urothelial cancer

astrazeneca
AstraZeneca and its global biologics research and development arm, MedImmune, today announced updated efficacy and safety data for durvalumab in patients with locally-advanced or metastatic urothelial...

AstraZeneca interested in Russian molecules for oncology

AstroZeneca in Skolkovo
AstraZeneca, a British-Swedish biopharmaceutical multinational, is interested in new molecules by Russian developers and considering investing more than $16m in an effort to localize production in the...